Candidate microRNA networks in cyclophosphamide-associated ovarian injury and premature ovarian insufficiency: a structured narrative review.
6 affiliations
- 1Departamento de Endocrinología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, 06720, Mexico.
- 2Unidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, 06720, Mexico.
- 3Laboratorio de Investigación en Biología Molecular, Hospital Infantil de México "Federico Gómez", Mexico City, 06720, Mexico.
- 4Departamento de Patología, Centro Médico Naval, Mexico City, 04470, Mexico.
- 5Departamento de Endocrinología, Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, 06720, Mexico.
- 6Unidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, 06720, Mexico. [email protected].
Abstract
Background
Premature ovarian insufficiency (POI) is characterized by loss of ovarian function before age 40, leading to infertility, hypoestrogenism, and long-term morbidity. Cyclophosphamide (CYC), an alkylating agent widely used in oncology and autoimmune diseases, is among the most gonadotoxic drugs. Beyond direct cytotoxicity, emerging evidence suggests that microRNAs (miRNAs) may modulate oxidative stress, apoptosis, autophagy, and inter-individual susceptibility to follicular loss after CYC exposure.Methods
We conducted a structured narrative review of PubMed, Scopus, and Web of Science records from 2015 to 2024, with targeted inclusion of relevant recent studies. We included in vitro, animal, and human evidence evaluating miRNA expression, regulation, or function in ovarian tissue, granulosa cells, circulating samples, or extracellular vesicles after CYC/chemotherapy-associated ovarian injury. Extracted variables included experimental model, exposure protocol, miRNA profile, targets, pathways, and functional outcomes. Review structure and critical appraisal were guided by SANRA.Results
CYC-induced ovarian injury involves oxidative stress, DNA damage, granulosa-cell apoptosis, impaired autophagy, stromal-vascular remodeling, and follicular depletion. Direct CYC-related evidence supports miR-15b and miR-122-5p as pro-injury mediators, while let-7a and miR-22-3p appear protective or restorable in specific experimental models. miR-10a, miR-21, and miR-144-5p are supported mainly as therapeutic or exosome-delivered protective cargos in preclinical chemotherapy-associated ovarian injury models. Other miRNAs, including miR-23a/27a, miR-146a/146b-5p, miR-483-5p, and miR-15a, provide contextual evidence from POI, granulosa-cell apoptosis, oxidative-stress, cisplatin, or non-CYC ovarian injury models. These miRNAs converge on α-Klotho/TGF-β-SMAD, PI3K/Akt, Wnt/β-catenin, NF-κβ, CMKLR1, STAT1, and PTEN-related pathways. Human evidence remains limited, mostly observational, and not CYC-specific.Conclusions
miRNAs are plausible epigenetic mediators of CYC-associated ovarian injury, but current data support a candidate regulatory network rather than a validated diagnostic, prognostic, or therapeutic signature. Circulating miRNAs remain exploratory biomarkers, and miRNA-targeted or exosome-based interventions require validation in human-relevant models before clinical translation. These molecular insights may inform future risk stratification, mechanistic monitoring, and post-treatment reproductive care in women exposed to alkylating agents.
Related
- Screening traditional Chinese medicine monomers for premature ovarian insufficiency: from network meta-analysis to the effects of a promising candidate on oxidative stress biomarkers
- Restoring fertility in premature ovarian insufficiency: Targeting the ovarian stroma with antifibrotic drugs
- Mitigating Environmental Pollutant-Induced Premature Ovarian Insufficiency by Rationally Designed Ultrasmall Gold Nanoparticles via Dual Regulation of ROS and Mitophagy.
- Genetics of Premature Ovarian Insufficiency: From Molecular Architecture to Precision Medicine.
- Research Progress of Stem Cell Therapy for Premature Ovarian Insufficiency.
BibTeX
@article{garciasaenz2026candidate,
title = {{Candidate microRNA networks in cyclophosphamide-associated ovarian injury and premature ovarian insufficiency: a structured narrative review.}},
author = {Manuel Ramón García-Sáenz and Claudia Ramírez-Rentería and Renata Saucedo and Jorge Valencia-Ortega and Nitzia López-Juárez and Aldo Ferreira-Hermosillo},
journal = {Journal of ovarian research},
year = {2026},
month = jul,
doi = {10.1186/s13048-026-02210-x},
url = {https://europepmc.org/article/MED/42907908},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Candidate microRNA networks in cyclophosphamide-associated ovarian injury and premature ovarian insufficiency: a structured narrative review.
AU - Manuel Ramón García-Sáenz
AU - Claudia Ramírez-Rentería
AU - Renata Saucedo
AU - Jorge Valencia-Ortega
AU - Nitzia López-Juárez
AU - Aldo Ferreira-Hermosillo
PY - 2026
DA - 2026/07/01
JO - Journal of ovarian research
DO - 10.1186/s13048-026-02210-x
UR - https://europepmc.org/article/MED/42907908
AB - Background Premature ovarian insufficiency (POI) is characterized by loss of ovarian function before age 40, leading to infertility, hypoestrogenism, and long-term morbidity. Cyclophosphamide (CYC), an alkylating agent widely used in oncology and autoimmune diseases, is among the most gonadotoxic drugs. Beyond direct cytotoxicity, emerging evidence suggests that microRNAs (miRNAs) may modulate oxidative stress, apoptosis, autophagy, and inter-individual susceptibility to follicular loss after CYC exposure.Methods We conducted a structured narrative review of PubMed, Scopus, and Web of Science records from 2015 to 2024, with targeted inclusion of relevant recent studies. We included in vitro, animal, and human evidence evaluating miRNA expression, regulation, or function in ovarian tissue, granulosa cells, circulating samples, or extracellular vesicles after CYC/chemotherapy-associated ovarian injury. Extracted variables included experimental model, exposure protocol, miRNA profile, targets, pathways, and functional outcomes. Review structure and critical appraisal were guided by SANRA.Results CYC-induced ovarian injury involves oxidative stress, DNA damage, granulosa-cell apoptosis, impaired autophagy, stromal-vascular remodeling, and follicular depletion. Direct CYC-related evidence supports miR-15b and miR-122-5p as pro-injury mediators, while let-7a and miR-22-3p appear protective or restorable in specific experimental models. miR-10a, miR-21, and miR-144-5p are supported mainly as therapeutic or exosome-delivered protective cargos in preclinical chemotherapy-associated ovarian injury models. Other miRNAs, including miR-23a/27a, miR-146a/146b-5p, miR-483-5p, and miR-15a, provide contextual evidence from POI, granulosa-cell apoptosis, oxidative-stress, cisplatin, or non-CYC ovarian injury models. These miRNAs converge on α-Klotho/TGF-β-SMAD, PI3K/Akt, Wnt/β-catenin, NF-κβ, CMKLR1, STAT1, and PTEN-related pathways. Human evidence remains limited, mostly observational, and not CYC-specific.Conclusions miRNAs are plausible epigenetic mediators of CYC-associated ovarian injury, but current data support a candidate regulatory network rather than a validated diagnostic, prognostic, or therapeutic signature. Circulating miRNAs remain exploratory biomarkers, and miRNA-targeted or exosome-based interventions require validation in human-relevant models before clinical translation. These molecular insights may inform future risk stratification, mechanistic monitoring, and post-treatment reproductive care in women exposed to alkylating agents.
SN - 1757-2215
ER -